Our collective results (Figs 1 and 2) suggest that targeting DR5 agonists against homogeneously sensitive tumor cells (having cytotoxicity above apoptotic threshold) will generate superior anti‐tumor cell death (Fig 3A). Here, TNFRSF10B is linked to neoplasm.